Approved for metastatic NSCLC with sensitive EGFR mutations, second-generation TKIs serve as alternatives to first-generation inhibitors, though their multitarget mechanism confers stronger adverse effects that may compromise patient tolerance [8]. Here, EGFR is linked to non-small cell lung carcinoma.